南新制药(688189.SH)收到中国证监会《立案告知书》

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation into alleged violations of annual report information disclosure laws [1] Group 1 - The CSRC has issued a "Notice of Case Filing" (No. 0132025024) against the company [1] - The investigation is based on suspicions of illegal information disclosure in the company's annual report [1] - The case is being pursued under the Securities Law of the People's Republic of China and the Administrative Penalty Law [1]